Becton Dickinson and Co at JPMorgan Healthcare Conference Transcript
Good morning, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Really happy to have Becton, Dickinson in our next session. Going to introduce Tom Polen, the CEO for a little talk, and then we'll do some Q&A afterwards. Tom?
Great. Thank you, Robbie, and it's great to be back in person. And thanks to everyone for your interest in BD. Today, I'm going to recap FY '22 and the strong momentum that we've built going into fiscal '23 as we continue to execute our BD2025 strategy. I'll emphasize our durable growth as we continue delivering category-leading products and transformative solutions that are at the forefront of modern health care.
Through our R&D and M&A strategies, we are accelerating our shift into attractive and higher-growth end markets, which is increasing our WAMGR and supporting our strong growth profile. What you should take away from my presentation is that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |